NEO vs. APDN, ULS, VKTX, ITCI, HQY, ENSG, MASI, JAZZ, BPMC, and RVMD
Should you be buying NeoGenomics stock or one of its competitors? The main competitors of NeoGenomics include Applied DNA Sciences (APDN), UL Solutions (ULS), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), HealthEquity (HQY), The Ensign Group (ENSG), Masimo (MASI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), and Revolution Medicines (RVMD).
NeoGenomics (NASDAQ:NEO) and Applied DNA Sciences (NASDAQ:APDN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability.
98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 22.2% of Applied DNA Sciences shares are held by institutional investors. 1.3% of NeoGenomics shares are held by company insiders. Comparatively, 10.3% of Applied DNA Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
NeoGenomics has a net margin of -13.79% compared to Applied DNA Sciences' net margin of -222.33%. NeoGenomics' return on equity of -3.54% beat Applied DNA Sciences' return on equity.
Applied DNA Sciences has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Applied DNA Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Applied DNA Sciences had 3 more articles in the media than NeoGenomics. MarketBeat recorded 7 mentions for Applied DNA Sciences and 4 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.28 beat Applied DNA Sciences' score of 0.51 indicating that NeoGenomics is being referred to more favorably in the media.
NeoGenomics currently has a consensus target price of $19.78, indicating a potential upside of 39.97%. Applied DNA Sciences has a consensus target price of $7.00, indicating a potential upside of 1,066.67%. Given Applied DNA Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Applied DNA Sciences is more favorable than NeoGenomics.
NeoGenomics received 204 more outperform votes than Applied DNA Sciences when rated by MarketBeat users. Likewise, 70.66% of users gave NeoGenomics an outperform vote while only 59.11% of users gave Applied DNA Sciences an outperform vote.
NeoGenomics has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Applied DNA Sciences has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.
Summary
NeoGenomics beats Applied DNA Sciences on 12 of the 18 factors compared between the two stocks.
Get NeoGenomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeoGenomics Competitors List
Related Companies and Tools
